Gastrointestinal endoscopy · 2019
ASGE guideline on the role of endoscopy in the evaluation and management of choledocholithiasis.
СтатьяКлинические рекомендацииПоддержка NIH: внешняя программаНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
ASGE Standards of Practice Committee, Buxbaum James L, Abbas Fehmi Syed M, Sultan Shahnaz, Fishman Douglas S, Qumseya Bashar J, Cortessis Victoria K, Schilperoort Hannah, Kysh Lynn, Matsuoka Lea, Yachimski Patrick, Agrawal Deepak, Gurudu Suryakanth R, Jamil Laith H, Jue Terry L, Khashab Mouen A, Law Joanna K, Lee Jeffrey K, Naveed Mariam, Sawhney Mandeep S, Thosani Nirav, Yang Julie, Wani Sachin B
Аннотация
Each year choledocholithiasis results in biliary obstruction, cholangitis, and pancreatitis in a significant number of patients. The primary treatment, ERCP, is minimally invasive but associated with adverse events in 6% to 15%. This American Society for Gastrointestinal Endoscopy (ASGE) Standard of Practice (SOP) Guideline provides evidence-based recommendations for the endoscopic evaluation and treatment of choledocholithiasis. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework was used to rigorously review and synthesize the contemporary literature regarding the following topics: EUS versus MRCP for diagnosis, the role of early ERCP in gallstone pancreatitis, endoscopic papillary dilation after sphincterotomy versus sphincterotomy alone for large bile duct stones, and impact of ERCP-guided intraductal therapy for large and difficult choledocholithiasis. Comprehensive systematic reviews were also performed to assess the following: same-admission cholecystectomy for gallstone pancreatitis, clinical predictors of choledocholithiasis, optimal timing of ERCP vis-à-vis cholecystectomy, management of Mirizzi syndrome and hepatolithiasis, and biliary stent therapy for choledocholithiasis. Core clinical questions were derived using an iterative process by the ASGE SOP Committee. This body developed all recommendations founded on the certainty of the evidence, balance of risks and harms, consideration of stakeholder preferences, resource utilization, and cost-effectiveness.